The tuberculosis Drugs Market is growing rapidly with the Global Alliance for TB Drug Development gaining the U.S. FDA approval for its Pretomanid Tablets
Tuberculosis (TB) is the most prevalent pulmonary tuberculosis disease. Because of the very difficult and lengthy period of survival after becoming infected with pulmonary tuberculosis (PTC) and the associated often severe pulmonary and immune system disorders, the management of tuberculosis often revolves around early initiation of treatment. One of the primary factors fueling growth of the market in discussion is rapidly growing cases of tuberculosis worldwide. As per the World Health Organization (WHO), in 2019, around 1.4 million people died from tuberculosis worldwide with around 10 million people being diagnosed with the same. Such massive incidence of tuberculosis cases across the globe could potentially stimulate the tuberculosis drugs market. As far as regional impact is considered, North America seems to be exhibiting significant traction in the tuberculosis drugs market . This can be attributed to the lower cost of TB drugs in the region. On the contrary, Asia Pacifi...